YTTRIUM Y 90 IBRITUMOMAB TIUXETAN

Search structure
Synonyms:
Status: Approved (2002)
Entry Type: Antibody
Molecule Category: UNKNOWN
UNII: QA846JAV5B

Pharmacology

Action Mechanism of Action Reference
BINDING AGENT B-lymphocyte antigen CD20 binding agent DailyMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Lymphoma, Non-Hodgkin 3 D008228 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Lymphoma, Follicular 2 D008224 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Graft vs Host Disease 2 D006086 ClinicalTrials
Leukemia, Lymphocytic, Chronic, B-Cell 2 D015451 ClinicalTrials
Burkitt Lymphoma 2 D002051 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 2 D016403 ClinicalTrials
Leukemia 2 D007938 ClinicalTrials
Lymphoma 2 D008223 ClinicalTrials
Multiple Myeloma 2 D009101 ClinicalTrials
Lymphoma, Large-Cell, Anaplastic 2 D017728 ClinicalTrials
Waldenstrom Macroglobulinemia 2 D008258 ClinicalTrials
Lymphoma, AIDS-Related 2 D016483 ClinicalTrials
Lymphoma, Mantle-Cell 2 D020522 ClinicalTrials
Lymphoma, B-Cell, Marginal Zone 1 D018442 ClinicalTrials
Hodgkin Disease 1 D006689 ClinicalTrials
Lymphoma, B-Cell, Marginal Zone 1 D018442 ClinicalTrials

Cross References

Resources Reference
ChEMBL CHEMBL2108667
FDA SRS QA846JAV5B
CONTENTS